HEALTH NEWS
Study Title:
FDA requires strong warnings for opioid analgesics, prescription opioid cough products, and benzodiazepine labeling related to serious risks and death from combined use.
Study Abstract
After an extensive review of the latest scientific evidence, the U.S. Food and Drug Administration announced today that it is requiring class-wide changes to drug labeling, including patient information, to help inform health care providers and patients of the serious risks associated with the combined use of certain opioid medications and a class of central nervous system (CNS) depressant drugs called benzodiazepines.
Study Information
FDA News ReleaseFull Study
https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm518697.htmRecent News
Arabinogalactan Boosts Lymph Flow and Immunity
Protect Your Gut Mucosal Barrier for Immune Health and Vitality
The Truth About Sugar Substitutes: Are Stevia, Sucralose, and Saccharin Safe?
Boost Your Digestive Power for Better Nutrient Absorption and Gut Health
MTHFR Gene and The Importance of Methyl B12 and Methyl Folate